ArticleCureus2026
Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary arterial hypertension (PAH) remains a progressive and potentially fatal disease despite currently available treatments. Both sotatercept and selexipag have demonstrated clinical benefits in randomized controlled trials (RCTs); however, no direct head-to-head trial has compared these agents. We therefore conducted an indirect comparison using reconstructed individual patient data.
methodsWe performed a systematic search of PubMed, Scopus, and EMBASE to identify placebo-controlled RCTs evaluating sotatercept or selexipag in PAH. Kaplan-Meier curves from eligible trials were digitized and analysed using the artificial-intelligence (AI) algorithm IPDfromKM to reconstruct individual patient data. Only participants classified as WHO functional class II or III were included. Heterogeneity among pooled placebo arms was assessed, and treatment effects were estimated using Cox regression. Results were reported as hazard ratios (HRs) with 95% confidence intervals (CIs).
resultsFour relevant RCTs were identified (STELLAR, GRIPHON, HYPERION, and ZENITH). STELLAR, GRIPHON, and HYPERION satisfied the inclusion criteria, whereas ZENITH was excluded because it enrolled patients in WHO functional class III or IV. Using IPDfromKM, we reconstructed the six study arms from the three included trials. Based on reconstructed data, placebo arms showed no significant heterogeneity (likelihood ratio = 0.64; p = 0.70). Compared with pooled placebo, selexipag and sotatercept produced HRs of 0.26 (95% CI 0.18-0.38) and 0.57 (95% CI 0.47-0.70), respectively. The main indirect comparison demonstrated a statistically significant benefit for sotatercept over selexipag (HR = 0.45; 95% CI 0.29-0.70; p = 0.00036).
conclusionsAI-based reconstruction of individual patient data made it possible to compare the efficacy of therapies in the absence of direct head-to-head evidence. These findings suggest that sotatercept may reduce PAH-related events more effectively than selexipag, although the inference is derived from reconstructed and indirectly compared data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.